The life saving COVID-19 drug, Ronapreve arrived in the Cayman Islands yesterday (November 18), bringing an added degree of hope to the country after the passing of two COVID-19 patients last weekend. The antibody treatment was popularized after it was part of the suite of experimental medicines given to former US president Donald Trump when he had COVID-19.
A combination of two monoclonal antibodies, Ronapreve, is typically targeted at those in hospital who have not mounted an antibody response against the coronavirus– but while it is used to treat or prevent acute COVID-19 infection, it isn’t a substitute for vaccination.
On November 15, Roche received marketing authorization from the European Commission for Ronapreve, to treat COVID-19 in adults and adolescents (12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of their disease becoming severe, and for preventing COVID-19 in people aged 12 years and older pre- or post-exposure prophylaxis.
Ronapreve was also approved for use in Japan and conditionally in the UK and Australia, and is authorized for emergency or temporary pandemic use in additional territories. Ronapreve, being jointly developed by Roche and Regeneron, is currently available in nearly 50 countries.
Initial clinical trial results showed Ronapreve can reduce risk of hospitalization and death due to COVID-19 by at least 70 per cent, says FDA chief Eric Domingo.
Subscribe and stay informed on Cayman Reopening.